{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"61"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"287"},{"groupId":"OG001","value":"287"}],"units":"Participants"}],"description":"Number of participants who received subsequent antineoplastic therapy was reported.","groups":[{"description":"Participants received ibrutinib 420 milligram (mg) (3 \\* 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.","id":"OG000","title":"Ibrutinib+BR"},{"description":"Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.","id":"OG001","title":"Placebo+BR"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all the randomized participants who received at least 1 dose of study drug or placebo.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Number of Participants Who Received Subsequent Antineoplastic Therapy","type":"SECONDARY","unitOfMeasure":"Participants"}